Abeona Therapeutics (ABEO): Visibility Improves Multiple, Raising PT - Maxim
Get Alerts ABEO Hot Sheet
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Maxim Group analyst, Jason McCarthy, reiterated his Buy rating on shares of Abeona Therapeutics (NASDAQ: ABEO) but raised his price target to $14 from $8 on reduced risk driving the multiple higher.
The analyst sees the "risk" in the Abeona story being reduced one patient and one data point at a time, resulting in a rising valuation. Over the next 12 months, multiple data points across several gene therapy programs should drive Abeona's valuation higher, as happened for AveXis, bluebird (NASDAQ: BLUE), Kite (NASDAQ: KITE), and Juno (NASDAQ: JUNO). The analyst reduced the risk in his model to 80%, from 90%, which increased the price target to $14, from $8. More data = lower risk = higher valuation.
For an analyst ratings summary and ratings history on Abeona Therapeutics click here. For more ratings news on Abeona Therapeutics click here.
Shares of Abeona Therapeutics closed at $5.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sage Therapeutics (SAGE) PT Lowered to $17 at Oppenheimer
- UnitedHealth Group (UNH) PT Raised to $571 at Piper Sandler
- Nicolet Bankshares (NIC) PT Lowered to $82.50 at Piper Sandler
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!